Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 10.75 NOK
Change Today -0.40 / -3.59%
Volume 87.0K
As of 10:25 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

pci biotech holding asa (PCIB) Snapshot

Open
11.00 NOK
Previous Close
11.15 NOK
Day High
11.00 NOK
Day Low
10.45 NOK
52 Week High
06/2/14 - 27.42 NOK
52 Week Low
12/17/14 - 9.45 NOK
Market Cap
158.3M
Average Volume 10 Days
10.1K
EPS TTM
-3.64 NOK
Shares Outstanding
14.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PCI BIOTECH HOLDING ASA (PCIB)

Related News

No related news articles were found.

pci biotech holding asa (PCIB) Related Businessweek News

No Related Businessweek News Found

pci biotech holding asa (PCIB) Details

PCI Biotech Holding ASA, an oncology-focused company, develops therapeutic products based on its proprietary photochemical internalization (PCI) technology. Its PCI technology induces triggered endosomal release, which enhances the therapeutic potential of various modalities, such as small molecules, ADCs, and siRNA. The company’s clinical study programs include phase II study of Amphinex based PCI with bleomycin to treat head and neck cancer; phase I/II study of Amphinex induced PCI of gemcitabine to treat bile duct cancer; and preclinical study of Cytotoxic T Lymphocytes for use in the treatment of cancers and other infectious diseases. It is also involved in the preclinical study on the delivery of macromolecules, such as proteins and nucleic acids; vaccine antigens; drugs carried by antibodies; and nanoparticles, as well as some small molecule drugs. The company has a pre-clinical research collaboration agreement with RXi Pharmaceuticals to explore potential synergies. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Lysaker, Norway.

11 Employees
Last Reported Date: 03/24/15
Founded in 2000

pci biotech holding asa (PCIB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 1.6M NOK
Chief Financial Officer
Total Annual Compensation: 237.0K NOK
Compensation as of Fiscal Year 2013.

pci biotech holding asa (PCIB) Key Developments

PCI Biotech Holding ASA Elects New Board of Directors

The Annual General Meeting in PCI Biotech Holding ASA took place on 12 May 2015. The meeting elected Hans Peter Bøhn and Christina Herder as new Board of Directors.

PCI Biotech Holding ASA Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

PCI Biotech Holding ASA reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported other income of NOK 2.614 million compared to NOK 1.967 million a year ago. Operating loss was NOK 7.710 million compared to NOK 9.409 million a year ago. Ordinary loss before taxes was NOK 7.655 million compared to NOK 9.248 million a year ago. Net loss was NOK 7.655 million compared to NOK 9.248 million a year ago. Loss per diluted share was NOK 0.68 compared to NOK 1.20 a year ago. Net cash outflow from operating activities were NOK 8.565 million compared to NOK 8.162 million a year ago. The increase in other income is due to a generally increased level both within of grants and the tax incentive scheme.

PCI Biotech Holding ASA Presents at Bio-Trinity, May-12-2015 03:10 PM

PCI Biotech Holding ASA Presents at Bio-Trinity, May-12-2015 03:10 PM. Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom. Speakers: Gael L'Heveder, Chief Business Development Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCIB:NO 10.75 NOK -0.40

PCIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PCIB.
View Industry Companies
 

Industry Analysis

PCIB

Industry Average

Valuation PCIB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.0x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PCI BIOTECH HOLDING ASA, please visit www.pcibiotech.no. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.